Cytek Biosciences (CTKB) Stock Price, News & Analysis

Company Overview

Cytek Biosciences, Inc. develops and manufactures cell analysis technologies for research, clinical, and biopharmaceutical applications. The company is best known for its full-spectrum flow cytometry platform, which captures a broader range of fluorescent light signals than conventional flow cytometers and is designed to support the analysis of complex cell populations.

Cytek’s product portfolio includes the Aurora and Northern Lights flow cytometers, which are available in configurations intended for a range of laboratory requirements. The company also provides cell-analysis software, fluorescence reagents, panels, and related consumables that support applications such as immunology, oncology, infectious disease research, cell and gene therapy development, and other areas of biomedical research.

Founded in 2011 and headquartered in Fremont, California, Cytek serves customers worldwide through direct operations and distribution partners. Its systems are used by academic and government research institutions, pharmaceutical and biotechnology companies, clinical laboratories, and other organizations conducting advanced cell analysis. Cytek became a publicly traded company on the Nasdaq in 2021.

Key Stats

• Today's Range: $5.23 to $5.48
• 50-Day Range: $4.16 to $6.09
• 52-Week Range: $3.31 to $6.21
• Volume: 1.07 million shs
• Average Volume: 1.08 million shs
• Market Capitalization: $701.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.56
• Consensus Rating: Hold

Cytek Biosciences Stock Analysis - MarketRank™

Cytek Biosciences scored higher than 33% of companies evaluated by MarketBeat, and ranked 775th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.6 / 5
• Analyst Rating: Hold

Consensus Rating

Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Cytek Biosciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Cytek Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cytek Biosciences are expected to grow in the coming year, from ($0.30) to ($0.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cytek Biosciences is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cytek Biosciences is -8.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cytek Biosciences has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.48% of the float of Cytek Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Cytek Biosciences has a short interest ratio ("days to cover") of 3.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cytek Biosciences has recently decreased by 0.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cytek Biosciences does not currently pay a dividend.

Dividend Growth

Cytek Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.86

News Sentiment

Cytek Biosciences has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for CTKB on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cytek Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.36% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:CTKB
• CIK: 1831915
• Web: www.cytekbio.com
• Phone: 877-922-9835
• Fax: N/A
• Employees: 702
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Cytek Biosciences: $5.56
• High Price Target: $7.50
• Low Price Target: $4.75
• Potential Upside/Downside: +3.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.54 million
• Net Margins: -38.98%
• Pretax Margin: -19.75%
• Return on Equity: -12.40%
• Return on Assets: -9.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.48
• Quick Ratio: 3.86

Sales & Book Value

• Annual Sales: $201.49 million
• Price / Sales: 3.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 2.02

Miscellaneous

• Outstanding Shares: 129,980,000
• Free Float: 116,517,000
• Market Cap: $701.89 million
• Optionable: Optionable
• Beta: 1.16